Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus.

NCT00044135 is registered in ClinicalTrials.gov with Triangle Pharmaceuticals as lead sponsor.

NCT NCT00044135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00044135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Partially-Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of 12 Weeks of Treatment with Clevudine (10 mg, 30 mg or 50 mg QD) in Patients Infected with Hepatitis B Virus.
Lead sponsor
Triangle Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2002
Completion date
Not reported
Enrollment
30
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b